ReCAP

 
 
  • Maintenance Therapy for Urothelial Carcinoma   Dr Scott Tagawa discusses maintenance therapies for urothelial carcinoma, including cisplatin, avelumab, pembrolizumab, and the newly approved combination enfortumab vedotin plus pembrolizumab.
  • Early Diagnosis and Treatment in Alzheimer's Disease   Breakthroughs that aid in early detection of Alzheimer's disease as well as the development of new disease-modifying therapies are poised to modify the course of Alzheimer's disease.
  • Efficacy and Safety Learnings From COVID-19 Vaccine Trials   Dr Karine Lacombe reviews global trial data on vaccine safety and efficacy against SARS-CoV-2 variants. She compares vaccine platforms, addresses rare adverse events, and discusses cellular immunity.
  • Survivorship in Veterans: Prostate Cancer   Prostate cancer experts share insights on optimal delivery of prostate cancer survivorship care to US veterans in an effort to alleviate psychological trauma and prevent treatment regret.
  • Long-Term Effects of COVID-19   Prof Matteo Bassetti discusses the long-term health effects of COVID-19, such as the multisystem condition known as long COVID, and the role of immunization in reducing the risk for COVID sequelae.
  • Risk Factors for Severe COVID-19   Prof Matteo Bassetti discusses the role of immunization in protecting those most at risk for severe COVID-19, including older adults, patients with comorbidities, and the immunocompromised.
  • Lung Fibrosis and Idiopathic Pulmonary Fibrosis   Dr Imre Noth discusses why slowing lung fibrosis in patients with idiopathic pulmonary fibrosis improves prognosis and reports on therapies that preserve lung function and slow disease progression.
  • Rapid Symptom Improvement in Major Depressive Disorder   Two unmet needs in major depressive disorder are options for patients who do not respond to standard medicine and faster onset of effect. Dr Michael Thase discusses new drugs that address these needs.
  • Treating Heart Failure in Patients With T2D and Renal Dysfunction   Dr Larry Allen discusses novel therapies that slow heart failure progression in patients with type 2 diabetes and renal dysfunction.
  • Diversity, Equity, and Inclusion in Colorectal Cancer Treatment   Racial disparities affect colorectal cancer outcomes, from screening to treatment and mortality. Dr Renee Williams discusses what physicians can do to modify these trends and increase health equity.
  • Combination Therapies for Patients With Type 2 Diabetes   Dr Chika Anekwe discusses when to combine antidiabetic therapies that have differing mechanisms, advantages of combination therapy, and the newest therapeutic options.
  • Inherited Retinal Diseases: Early Signs and Treatment   New therapies to treat inherited retinal diseases are in development in the wake of excitement over the benefits some patients are receiving from the one approved medication in this setting.
  • Reducing Hospitalization in Heart Failure   A new class of drugs and improvements in patient management have led to a reduction of recurrent readmissions for heart failure, according to Dr Clyde Yancy of Northwestern University.
  • Managing Iron Deficiency in Patients With Heart Failure   Dr Theresa McDonagh highlights iron supplementation trials examining the effects of intravenous ferric carboxymaltose, as well as new ESC guidelines for iron deficiency, in patients with heart failure.
  • Selecting Biologics in Active Psoriatic Arthritis   Active psoriatic arthritis is highly heterogeneous and linked to multiple conditions. Prof Laura Coates explains how biologics can be individualized to a patient's comorbidities to improve outcomes.
  • Non-Insulin Treatment Adherence in Type 2 Diabetes   Non-insulin treatment adherence is a challenge for many patients with type 2 diabetes. Dr Anne Peters offers clinicians tips for overcoming some of the barriers.
  • Managing Patients With Obesity and Impaired Renal Function   Dr Alex Chang discusses the importance of weight reduction in patients with obesity and impaired renal function as well as available therapies that address both conditions.
  • Obesity Management in Youth-Onset Type 2 Diabetes   Current treatment and behavioral guidelines for youth-onset type 2 diabetes and obesity management, including liraglutide, dulaglutide, and exenatide, are discussed by Dr Amy S. Shah.
  • Endocrine Therapy Resistance in HR+/HER2- Breast Cancer   Oncologist Jennifer Litton discusses endocrine therapy and CDK4/6 inhibitors in hormone receptor–positive breast cancer, drivers of endocrine resistance, and the role of genetic testing in treatment selection.
  • Emerging Therapies for Alzheimer's Disease   Dr Pierre Tariot of the Banner Alzheimer's Institute reviews data on new and emerging therapies for Alzheimer's disease, including recently approved anti-amyloid therapies.